Last reviewed · How we verify
Inactivated Coronavac/Butantan vaccine
An inactivated whole-virus SARS-CoV-2 vaccine that stimulates adaptive immune responses to prevent COVID-19 infection.
An inactivated whole-virus SARS-CoV-2 vaccine that stimulates adaptive immune responses to prevent COVID-19 infection. Used for COVID-19 prevention in adults and children.
At a glance
| Generic name | Inactivated Coronavac/Butantan vaccine |
|---|---|
| Sponsor | Federal University of Espirito Santo |
| Drug class | inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CoronaVac is produced by inactivating SARS-CoV-2 virus particles, which are then administered to trigger both humoral (antibody) and cellular (T-cell) immune responses against viral antigens. This approach allows the immune system to recognize and neutralize the virus upon natural exposure, reducing infection risk and disease severity.
Approved indications
- COVID-19 prevention in adults and children
Common side effects
- Injection site pain or swelling
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: